Literature DB >> 30710068

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Ramon Colomer1, Cristina Saura2, Pedro Sánchez-Rovira3, Tomás Pascual4,5, Isabel T Rubio6, Octavio Burgués7, Lourdes Marcos8, César A Rodríguez9, Miguel Martín10, Ana Lluch11.   

Abstract

BACKGROUND: Neoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.
DESIGN: A panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.
RESULTS: Neoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conservation, assessing tumor response, establishing prognosis based on the pathological response, and providing a "second opportunity" for nonresponding patients. Achieving pathological complete remission because of neoadjuvant therapy has been correlated with long-term clinical benefit, particularly in HER2-positive and triple-negative breast cancer. In addition, the neoadjuvant setting is a powerful model for the development of new drugs and the identification of prognostic markers. Finally, neoadjuvant therapy has proven to be cost-effective by reducing nondrug costs, avoiding radical surgery, and reducing hospital stays when compared with other treatment approaches.
CONCLUSION: Neoadjuvant therapy has clinical benefits in early breast cancer and provides in vivo information of individual breast cancer biology while allowing the investigation of new treatment approaches. Access to neoadjuvant therapy should be an option available to all patients with breast cancer through multidisciplinary tumor management. IMPLICATIONS FOR PRACTICE: Neoadjuvant treatment should be strongly considered as a therapeutic option for localized breast cancer and is a powerful tool for understanding breast cancer biology and investigating new treatment approaches. © AlphaMed Press 2019.

Entities:  

Keywords:  Chemotherapy; Cost analysis; HER therapy; Hormonal therapy; Surgery

Mesh:

Year:  2019        PMID: 30710068      PMCID: PMC6516119          DOI: 10.1634/theoncologist.2018-0228

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  87 in total

1.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Senkus; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; E Rutgers; S Zackrisson; F Cardoso
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).

Authors:  Peter Beitsch; Pat Whitworth; Paul Baron; Michael C Rotkis; Angela M Mislowsky; Paul D Richards; Mary K Murray; James V Pellicane; Carrie L Dul; Charles H Nash; Lisette Stork-Sloots; Femke de Snoo; Sarah Untch; Laura A Lee
Journal:  Ann Surg Oncol       Date:  2017-04-26       Impact factor: 5.344

3.  Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.

Authors:  Duveken B Y Fontein; Ayoub Charehbili; Johan W R Nortier; Elma Meershoek-Klein Kranenbarg; Judith R Kroep; H Putter; Yvonne van Riet; Grard A P Nieuwenhuijzen; Bart de Valk; Jetske M Meerum Terwogt; Gijs D Algie; Gerrit-Jan Liefers; Sabine Linn; Cornelis J H van de Velde
Journal:  Eur J Cancer       Date:  2014-06-23       Impact factor: 9.162

4.  Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.

Authors:  Elizabeth A Mittendorf; Thomas A Buchholz; Susan L Tucker; Funda Meric-Bernstam; Henry M Kuerer; Ana M Gonzalez-Angulo; Isabelle Bedrosian; Gildy V Babiera; Karen Hoffman; Min Yi; Merrick I Ross; Gabriel N Hortobagyi; Kelly K Hunt
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

5.  [EUSOMA requirements for breast cancer units in Spain].

Authors:  Belén Merck; José Manuel Ramos-Rincón; Pilar Cansado; Juan Blas Ballester; Francisco Martínez-García; Manuel Ramos-Boyero; Rafael Calpena
Journal:  Cir Esp       Date:  2005-04       Impact factor: 1.653

6.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

7.  Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

Authors:  E Alba; L Calvo; J Albanell; J R De la Haba; A Arcusa Lanza; J I Chacon; P Sanchez-Rovira; A Plazaola; J A Lopez Garcia-Asenjo; B Bermejo; E Carrasco; A Lluch
Journal:  Ann Oncol       Date:  2012-06-06       Impact factor: 32.976

8.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Authors:  David Cameron; Julia Brown; Rebecca Dent; Christian Jackisch; John Mackey; Xavier Pivot; Guenther G Steger; Thomas M Suter; Masakazu Toi; Mahesh Parmar; Rita Laeufle; Young-Hyuck Im; Gilles Romieu; Vernon Harvey; Oleg Lipatov; Tadeusz Pienkowski; Paul Cottu; Arlene Chan; Seock-Ah Im; Peter S Hall; Lida Bubuteishvili-Pacaud; Volkmar Henschel; Regula J Deurloo; Celine Pallaud; Richard Bell
Journal:  Lancet Oncol       Date:  2013-08-07       Impact factor: 41.316

9.  Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

Authors:  George S Karagiannis; Jessica M Pastoriza; Yarong Wang; Allison S Harney; David Entenberg; Jeanine Pignatelli; Ved P Sharma; Emily A Xue; Esther Cheng; Timothy M D'Alfonso; Joan G Jones; Jesus Anampa; Thomas E Rohan; Joseph A Sparano; John S Condeelis; Maja H Oktay
Journal:  Sci Transl Med       Date:  2017-07-05       Impact factor: 17.956

10.  Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.

Authors:  Aiko Nagayama; Tetsu Hayashida; Hiromitsu Jinno; Maiko Takahashi; Tomoko Seki; Akiko Matsumoto; Takeshi Murata; Hutan Ashrafian; Thanos Athanasiou; Koji Okabayashi; Yuko Kitagawa
Journal:  J Natl Cancer Inst       Date:  2014-09-15       Impact factor: 13.506

View more
  14 in total

1.  Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response?

Authors:  Anna D'Angelo; Armando Orlandi; Enida Bufi; Sara Mercogliano; Paolo Belli; Riccardo Manfredi
Journal:  Radiol Med       Date:  2021-01-01       Impact factor: 3.469

2.  Surgical margin status and survival outcomes of breast cancer patients treated with breast-conserving surgery and whole-breast irradiation after neoadjuvant chemotherapy.

Authors:  Jong-Ho Cheun; Young Joo Lee; Jun-Hee Lee; Yungil Shin; Jung Whan Chun; Soo Yeon Baek; Hong-Kyu Kim; Han-Byoel Lee; Jonghan Yu; Byung Joo Chae; Wonshik Han; Jeong Eon Lee
Journal:  Breast Cancer Res Treat       Date:  2022-06-28       Impact factor: 4.624

Review 3.  miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.

Authors:  Zhuo Zhang; Hanxu Zhang; Jiao Yu; Ling Xu; Xiaocong Pang; Qian Xiang; Qianxin Liu; Yimin Cui
Journal:  Breast Cancer Res Treat       Date:  2022-06-21       Impact factor: 4.624

4.  SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.

Authors:  Tomás Pascual; Mafalda Oliveira; Eva Ciruelos; Meritxell Bellet Ezquerra; Cristina Saura; Joaquin Gavilá; Sonia Pernas; Montserrat Muñoz; Maria J Vidal; Mireia Margelí Vila; Juan M Cejalvo; Blanca González-Farré; Martin Espinosa-Bravo; Josefina Cruz; Francisco Javier Salvador-Bofill; Juan Antonio Guerra; Ana María Luna Barrera; Miriam Arumi de Dios; Stephen Esker; Pang-Dian Fan; Olga Martínez-Sáez; Guillermo Villacampa; Laia Paré; Juan M Ferrero-Cafiero; Patricia Villagrasa; Aleix Prat
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

5.  Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy.

Authors:  Shan Zhang; Yaohui Wang; Yan Wang; Jing Peng; Chenwei Yuan; Liheng Zhou; Shuguang Xu; Yanping Lin; Yueyao Du; Fan Yang; Jie Zhang; Huijuan Dai; Wenjin Yin; Jinsong Lu
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

6.  Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer.

Authors:  Karla B Peña; Amillano Kepa; Alba Cochs; Francesc Riu; David Parada; Josep Gumà
Journal:  Genes (Basel)       Date:  2021-01-08       Impact factor: 4.096

7.  Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.

Authors:  Zhuo Zhang; Hanxu Zhang; Chao Li; Qian Xiang; Ling Xu; Qianxin Liu; Xiaocong Pang; Wenjia Zhang; Hong Zhang; Shuang Zhang; Xuening Duan; Yinhua Liu; Yimin Cui
Journal:  Thorac Cancer       Date:  2021-11-09       Impact factor: 3.500

8.  Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Jie Dong; Qingqing Sun; Yueyin Pan; Nannan Lu; Xinghua Han; Qiong Zhou
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

9.  2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.

Authors:  Semir Bešlija; Zdenka Gojković; Timur Cerić; Alma Mekić Abazović; Inga Marijanović; Semir Vranić; Jasminka Mustedanagić-Mujanović; Faruk Skenderi; Ivanka Rakita; Aleksandar Guzijan; Dijana Koprić; Alen Humačkić; Danijela Trokić; Jasmina Alidžanović; Alma Efendić; Ibrahim Šišić; Harun Drljević; Vanesa Bešlagić; Božana Babić; Azra Pašić; Anela Ramić; Dijana Mikić; Zlatko Guzin; Dragana Karan; Teo Buhovac; Dragana Miletić; Senad Šečić; Azra Đozić Šahmić; Lejla Mujbegović; Alisa Kubura; Mensura Burina; Nenad Lalović; Nikolina Dukić; Jelena Vladičić Mašić; Mirjana Ćuk; Rajna Stanušić
Journal:  Bosn J Basic Med Sci       Date:  2021-04-01       Impact factor: 3.363

10.  Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy.

Authors:  Lun Li; Min Chen; Shuyue Zheng; Hanlu Li; Weiru Chi; Bingqiu Xiu; Qi Zhang; Jianjing Hou; Jia Wang; Jiong Wu
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.